Genscript Biotech Corpora... (GNNSF)
Genscript Biotech Statistics
Share Statistics
Genscript Biotech has 2.14B shares outstanding. The number of shares has increased by 0.73% in one year.
| Shares Outstanding | 2.14B |
| Shares Change (YoY) | 0.73% |
| Shares Change (QoQ) | 0.16% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 1.1B |
| Failed to Deliver (FTD) Shares | - |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 0.91 and the forward PE ratio is null. Genscript Biotech's PEG ratio is 0.
| PE Ratio | 0.91 |
| Forward PE | n/a |
| PS Ratio | 4.53 |
| Forward PS | n/a |
| PB Ratio | 0.62 |
| P/FCF Ratio | -37.28 |
| PEG Ratio | 0 |
Enterprise Valuation
Genscript Biotech has an Enterprise Value (EV) of 2.73B.
| EV / Sales | 4.6 |
| EV / EBITDA | -32.11 |
| EV / EBIT | 36.12 |
| EV / FCF | -37.81 |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.04.
| Current Ratio | 2.72 |
| Quick Ratio | 2.62 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | -2 |
| Debt / FCF | -2.36 |
| Interest Coverage | 2.83 |
Financial Efficiency
Return on Equity is 68.54% and Return on Invested Capital is 0.46%.
| Return on Equity | 68.54% |
| Return on Assets | 56.11% |
| Return on Invested Capital | 0.46% |
| Revenue Per Employee | $106.77K |
| Profits Per Employee | $531.95K |
| Employee Count | 5,568 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 10.37 |
Taxes
| Income Tax | 2.98M |
| Effective Tax Rate | -1.74% |
Stock Price Statistics
The stock price has increased by -13.91% in the last 52 weeks. The beta is 1.02, so Genscript Biotech's price volatility has been higher than the market average.
| Beta | 1.02 |
| 52-Week Price Change | -13.91% |
| 50-Day Moving Average | 1.53 |
| 200-Day Moving Average | 1.45 |
| Relative Strength Index (RSI) | 31.36 |
| Average Volume (20 Days) | 545 |
Income Statement
In the last 12 months, Genscript Biotech had revenue of 594.49M and earned 2.96B in profits. Earnings per share was 1.4.
| Revenue | 594.49M |
| Gross Profit | 272.13M |
| Operating Income | 22.71M |
| Net Income | 2.96B |
| EBITDA | -85.09M |
| EBIT | -162.76M |
| Earnings Per Share (EPS) | 1.4 |
Balance Sheet
The company has 131.99M in cash and 170.57M in debt, giving a net cash position of -38.58M.
| Cash & Cash Equivalents | 131.99M |
| Total Debt | 170.57M |
| Net Cash | -38.58M |
| Retained Earnings | 2.35B |
| Total Assets | 5.28B |
| Working Capital | 527.64M |
Cash Flow
In the last 12 months, operating cash flow was 75.65M and capital expenditures -147.92M, giving a free cash flow of -72.27M.
| Operating Cash Flow | 75.65M |
| Capital Expenditures | -147.92M |
| Free Cash Flow | -72.27M |
| FCF Per Share | -0.03 |
Margins
Gross margin is 45.77%, with operating and profit margins of 3.82% and 498.22%.
| Gross Margin | 45.77% |
| Operating Margin | 3.82% |
| Pretax Margin | -28.73% |
| Profit Margin | 498.22% |
| EBITDA Margin | -14.31% |
| EBIT Margin | 3.82% |
| FCF Margin | -12.16% |
Dividends & Yields
GNNSF does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 109.94% |
| FCF Yield | -2.68% |
Analyst Forecast
Currently there are no analyst rating for GNNSF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 2.4 |
| Piotroski F-Score | 2 |